Systemic inflammatory response and elevated tumour markers predict worse survival in resectable pancreatic ductal adenocarcinoma

PLoS ONE

Volumn 11, Issue 9, 2016, Pages

  Salmiheimo, Aino ^a   Mustonen, Harri ^a   Stenman, Ulf Håkan ^a   Puolakkainen, Pauli ^a   Kemppainen, Esko ^a   Seppänen, Hanna ^a   Haglund, Caj ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CA 19-9 ANTIGEN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; GEMCITABINE; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; FEMALE; GLASGOW PROGNOSTIC SCORE; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; INFLAMMATION; LYMPH NODE METASTASIS; LYMPH NODE RATIO; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PROGNOSTIC ASSESSMENT; RETROSPECTIVE STUDY; SURVIVAL TIME; METABOLISM; MULTIVARIATE ANALYSIS; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS;

AGED; BIOMARKERS, TUMOR; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84988922208     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0163064     Document Type: Article

References (37)

1. Cancer Research UK. Pancreatic cancer mortality statistics. Available: http://www.cancerresearchuk. org/cancer-info/cancerstats/types/pancreas/mortality.Accessed 08/01, 2016.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan-Feb; 66(1):7-30. doi: 10.3322/caac.21332 PMID: 26742998
3. Seppänen H, Juuti A, Mustonen H, Haapamäki C, Nordling S, Carpelan-Holmström M, et al. The Results of Pancreatic Resections and Long-Term Survival for Pancreatic Ductal Adenocarcinoma: A Single-Institution Experience. Scand J Surg. Epub 2016 Apr 29. doi: 10.1177/1457496916645963
4. GebhardtC, MeyerW, Reichel M,Wunsch PH. Prognostic factors in the operative treatment of ductal pancreatic carcinoma. Langenbecks Arch Surg. 2000 Jan; 385(1):14-20. PMID: 10664114
5. Garcea G, Dennison AR, Pattenden CJ, Neal CP, Sutton CD, BerryDP. Survival following curative resection for pancreatic ductal adenocarcinoma.A systematic review of the literature. JOP. 2008; 9 (2):99-132. PMID: 18326920
6. Benassai G, QuartoG, Perrotta S, Furino E, Benassai GL, Amato B, et al. Long-termsurvival after curative resection for pancreatic ductal adenocarcinoma-Surgical treatment. Int J Surg. 2015 Sep; 21 (Suppl 1):S1-3. doi: 10.1016/j.ijsu.2015.06.050 PMID: 26118618
7. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013 Nov; 13(11):759-771. doi: 10.1038/nrc3611 PMID: 24154716
8. Coussens LM,Werb Z. Inflammation and cancer. Nature. 2002 Dec 19-26; 420(6917):860-867. PMID: 12490959
9. Atsumi T, Singh R, Sabharwal L, Bando H, Meng J, ArimaY, et al. Inflammation amplifier, a new paradigm in cancer biology. Cancer Res. 2014 Jan 1; 74(1):8-14. doi: 10.1158/0008-5472.CAN-13-2322 PMID: 24362915
10. Kersten C, Louhimo J, Algars A, Lahdesmaki A, Cvancerova M, Stenstedt K, et al. Increased C-reactive protein implies a poorer stage-specific prognosis in colon cancer. Acta Oncol. 2013 Nov; 52(8):1691-1698. doi: 10.3109/0284186X.2013.835494 PMID: 24102179
11. Saito K, Kihara K. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes. Int J Urol. 2013 Feb; 20(2):161-171. doi: 10.1111/j.1442-2042.2012.03121.x PMID: 22897628
12. Han Y, Mao F, Wu Y, Fu X, Zhu X, Zhou S, et al. Prognostic role of C-reactive protein in breast cancer: a systematic review and meta-analysis. Int J Biol Markers. 2011 Oct-Dec; 26(4):209-215. doi: 10.5301/JBM.2011.8872 PMID: 22139643
13. Haas M, Heinemann V, Kullmann F, LaubenderRP, Klose C, Bruns CJ, et al. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol. 2013 Apr; 139(4):681-689. doi: 10.1007/s00432-012-1371-3 PMID: 23315099
14. Stevens L, Pathak S, Nunes QM, Pandanaboyana S, Macutkiewicz C, Smart N, et al. Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: a systematic review. HPB. 2015 Apr; 17(4):285-291. doi: 10.1111/hpb.12355 PMID: 25431369
15. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999 Feb 11; 340(6):448-454. PMID: 9971870
16. Forrest LM, McMillanDC, McArdle CS, AngersonWJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003 Sep 15; 89(6):1028-1030. PMID: 12966420
17. McMillanDC, Crozier JE, Canna K, AngersonWJ, McArdle CS. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 2007 Aug; 22(8):881-886. PMID: 17245566
18. Proctor MJ, MorrisonDS, Talwar D, Balmer SM, O'Reilly DS, Foulis AK, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer. 2011 Feb 15; 104(4):726-734. doi: 10.1038/sj.bjc.6606087 PMID: 21266974
19. Magnani JL, Steplewski Z, Koprowski H, Ginsburg V. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res. 1983 Nov; 43(11):5489-5492. PMID: 6193872
20. Lundin J, RobertsPJ, Kuusela P, Haglund C. The prognostic value of preoperative serumlevels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer. 1994 Mar; 69(3):515-519. PMID: 7510116
21. Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology. 2006; 70(4):255-264. PMID: 16899980
22. Humphris JL, Chang DK, Johns AL, ScarlettCJ, Pajic M, JonesMD, et al. The prognostic and predictive value of serumCA19.9 in pancreatic cancer. Ann Oncol. 2012 Jul; 23(7):1713-1722. doi: 10.1093/annonc/mdr561 PMID: 22241899
23. Altman DG, McShane LM, SauerbreiW, Taube SE. ReportingRecommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med. 2012; 9(5):e1001216. doi: 10. 1371/journal.pmed.1001216 PMID: 22675273
24. Doumatey AP, Zhou J, Adeyemo A, RotimiC. High sensitivity C-reactive protein (Hs-CRP) remains highly stable in long-termarchived human serum. Clin Biochem. 2014 3; 47(4-5):315-318. doi: 10. 1016/j.clinbiochem.2013.12.014 PMID: 24373927
25. Diakos CI, Charles KA, McMillanDC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014 Oct; 15(11):e493-503. doi: 10.1016/S1470-2045(14)70263-3 PMID: 25281468
26. Neesse A, Algul H, Tuveson DA, Gress TM. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut. 2015 Sep; 64(9):1476-1484. doi: 10.1136/gutjnl-2015-309304 PMID: 25994217
27. Laird BJ, McMillan DC, Fayers P, Fearon K, Kaasa S, Fallon MT, et al. The systemic inflammatory response and its relationship to pain and other symptoms in advanced cancer. Oncologist. 2013; 18 (9):1050-1055. doi: 10.1634/theoncologist.2013-0120 PMID: 23966223
28. Bower JE, Lamkin DM. Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain Behav Immun. 2013 Mar; 30(Suppl):S48-57. doi: 10.1016/j.bbi.2012.06. 011 PMID: 22776268
29. Ruiz-Tovar J, Martin-Perez E, Fernandez-Contreras ME, Reguero-Callejas ME, Gamallo-Amat C. Impact of preoperative levels of hemoglobin and albumin on the survival of pancreatic carcinoma. Revista Espanola de Enfermedades Digestivas. 2010 Nov; 102(11):631-636. PMID: 21142383
30. Sanjay P, de FigueiredoRS, Leaver H, Ogston S, Kulli C, Polignano FM, et al. Preoperative serumCreactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.JOP. 2012 Mar; 13(2):199-204. PMID: 22406601
31. Szkandera J, Stotz M, Absenger G, Stojakovic T, Samonigg H, Kornprat P, et al. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Br J Cancer. 2014 Jan 7; 110(1):183-188. doi: 10.1038/bjc.2013.701 PMID: 24201751
32. La Torre M, Nigri G, Cavallini M, MercantiniP, Ziparo V, Ramacciato G. The glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2012 Sep; 19(9):2917-2923. doi: 10.1245/s10434-012-2348-9 PMID: 22488099
33. Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primaryoperable and inoperable pancreatic cancer. Br J Cancer. 2013 Jul 23; 109(2):416-421. doi: 10.1038/bjc.2013.332 PMID: 23799847
34. Mor V, Laliberte L, Morris JN, Wiemann M. The KarnofskyPerformance Status Scale. An examination of its reliability and validity in a research setting. Cancer. 1984 May 1; 53(9):2002-2007. PMID: 6704925
35. Liu L, Xu H,WangW, Wu C, Chen Y, Yang J, et al. A preoperative serumsignature of CEA+/CA125 +/CA19-9>1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Int J Cancer. 2015 May 1; 136(9):2216-2227. doi: 10.1002/ijc.29242 PMID: 25273947
36. Riediger H, Keck T, Wellner U, zur Hausen A, AdamU, Hopt UT, et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg. 2009 Jul; 13(7):1337-1344. doi: 10.1007/s11605-009-0919-2 PMID: 19418101
37. Bockhorn M, Uzunoglu FG, Adham M, ImrieC, Milicevic M, Sandberg AA, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014 Jun; 155(6):977-988. doi: 10.1016/j.surg.2014.02.001 PMID: 24856119